Contact: info@alspinc.com
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
vvvNeurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
44M people world wide
...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included.

44M people world wide


-
...TBI increases risk of dementia by as much as two-fold
  
44M people world wide
44M People World Wide

...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included...

Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 

 

        NEWS AND EVENTS

 

          September 30, 2018: American Life Science Pharmaceuticals (ALSP) is pleased to announce that it recently has been awarded a Small Business Technology Transfer (STTR) Phase I grant from the National Institute of Neurological Disease (NINDS) at the National Institutes of Health, Bethesda, MD. The grant is entitled “Cathepsin B inhibitor Drug Development for Traumatic Brain Injury” and is led by Principal Investigator, Dr. Greg Hook, JD, Ph.D., Vice President of Research at ALSP.  The grant is a collaboration with the University of California, San Diego (UCSD), which has a grant subcontract, led by Vivian Hook, Ph.D., Distinguished Professor, The Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD.  The grant will establish proof-of-principal for the development of an entirely new class of TBI therapeutics. April, 2017: ALSP announced that it has had the great good fortune to have Steve Jacobsen, Ph.D. accept the position of CEO and take a seat on its Board. Steve has been advising the Company for a number of years and became available when he left his position as Senior Project Director of Neuroscience iMed at AstraZeneca. Steve brings with him many years' experience in drug development for neurodegeneration and a world class reputation in the space, and we are proud to welcome him onboard. Dr. Pierschbacher will remain with the Company and is very much looking forward to working with Steve in his new leadership capacity. June, 2016: Vivian Hook, Ph.D., UCSD, and Gregory Hook, Ph.D., ALSP Inc., will present scientific papers at the National Neurotrauma Society Meeting, June 26-29, 2016, in Lexington, Kentucky, and at the Gordon Research Conference on Neurobiology of Brain Disorders, August 7-12, 2016, in Girona, Spain. 

looking forward to working with Steve in his new leadership capacity.
a number of years and became available when he left his position as Senior Project Director of Neuroscience iMed at AstraZeneca. Steve brings with him many years' experience in drug development for neurodegeneration and a world class reputation in the space, and we are proud to welcome him onboard. Dr. Pierschbacher will remain with the Company and is very much looking forward to working with Steve in his new leadership capacity.
April, 2017: ALSP announced that it has had the great good fortune to have Steve Jacobsen, Ph.D. accept the position of CEO and take a seat on its Board. Steve has been advising the Company for a number of years and became available when he left his position as Senior Project Director of Neuroscience iMed at AstraZeneca. Steve brings with him many years' experience in drug development for neurodegeneration and a world class reputation in the space, and we are proud to welcome him onboard. Dr. Pierschbacher will remain with the Company and is very much looking forward to working with Steve in his new leadership capacity.

April, 2017: ALSP announced that it has had the great good fortune to have Steve Jacobsen, Ph.D. accept the position of CEO and take a seat on its Board. Steve has been advising the Company for a number of years and became available when he left his position as Senior Project Director of Neuroscience iMed at AstraZeneca. Steve brings with him many years' experience in drug development for neurodegeneration and a world class reputation in the space, and we are proud to welcome him onboard. Dr. Pierschbacher will remain with the Company and is very much looking forward to working with Steve in his new leadership capacity.
            April 6, 2016: ALSP, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims directed to a

          group of ALP-496-related compounds, which ALSP had earlier licensed from Columbia University. Michael Pierschbacher, Ph.D, CEO, stated,

          "This issuance significantly increases the depth of our patent-approved pipeline of potential drug candidates." Read More... 


          March 1 - 2, 2016: ALSP Inc. presented its recent research findings at the 'GTC 2nd Protease Inhibitors in Drug Discovery' meeting in San Diego.

          As a Keynote speaker, Vivian Hook, Ph.D., UCSD, presented "Cathepsin B is a Validated Drug Target for Traumatic Brain Injury" and Gregory Hook,

          Ph.D., ALSP Inc., presented the poster "E64d, a Cysteine Protease Inhibitor, Provides a Viable Translational Opportunity for Development of

          Therapeutics for TBI". Read More...


          The following abstracts are available:


          Cathepsin B is a Validated Drug Target for Traumatic Brain Injury (TBI) and TBI-Related Brain Disorders
          E64d is a Translational Opportunity for Traumatic Brain Injury (TBI) Drug Development

                          

                                                                                              

          February 10, 2016: ALSP Inc. announced that it has appointed Col.(Retired) Dallas C. Hack, MD as Consultant for Medical Affairs

          in preparation for its move into clinical trials with its lead drug. Michael Pierschbacher, PhD, CEO, stated, "We are pleased to welcome Dallas Hack

          onto the ALSP team. We look forward to working with an individual of such practical knowledge and far-reaching experience in Traumatic Brain Injury

          (TBI). We look forward to drawing deeply on his broad experience and success as a clinician and researcher in this area as we enter into our next

          stage of growth, clinical development." Read More...


                                                                                                                  

          January 25 - 27, 2016: ALSP Inc. presented its recent research findings at the Keystone Symposia on Molecular and Cellular Biology in Santa Fe,

          New Mexico. Vivian Hook, Ph.D. UCSD, presented "Cathepsin B is a Validated Drug Target for Traumatic Brain Injury" during a session entitled

          "From Precision Medicine to Therapies (TBI)". Gregory Hook, Ph.D., ALSP, presented the poster "E64d, a Cysteine Protease Inhibitor, Provides a

          Viable Translational Opportunity for Development of Therapeutics for TBI", reviewing small molecule cysteine protease inhibitors shown to be

          effective in a number of TBI-related animal models and describing the selection of a lead clinical candidate. Read More...


          The following abstracts are available:


          Cathepsin B is a Validated Drug Target for Traumatic Brain Injury (TBI) and TBI-Related Brain Disorders

          E64d is a Translational Opportunity for Traumatic Brain Injury (TBI) Drug Development


                                                                                                          

t


2012


2011


2010


2008 - 2009

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.


>Deletion of the cathepsin B gene improves memory deficits in an Alzheimer's disease (AD) mouse model expressing APP with the wild-type beta-secretase site, representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

***